| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M QUIZARTINIB (is an active metabolite)
| QUIZARTINIB | ANTINEOPLASTIC | - | Cmax 282 NANOMOLAR Tmax 5.5 HOUR PPB 99 PERCENT HT 136 HOUR | TYROSINE KINASE FLT3 | Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| QUIZARTINIB (has an active metabolite)
| QUIZARTINIB | ANTINEOPLASTIC | ORAL | Cmax 249 NANOMOLAR Tmax 4 HOUR F 71 PERCENT VD 275 LITER PPB 99 PERCENT Cl 2.23 LITER / HOUR HT 81 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER | TYROSINE KINASE FLT3 PDB 4XUF (CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)) LIGAND CODE = P30 (link to the list of PDB complexes) Download experimental 3D coordinates of P30 with added hydrogens | Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral | EMA | |||
